| Literature DB >> 35204925 |
Yu-Te Huang1, Hui-Ju Lin1, Wen-Ling Liao2,3, Yi-Yu Tsai1, Yi-Ching Hsieh1.
Abstract
BACKGROUND: In this study we aim to determines the effect of our vision therapy program for 7- to 10-year-old patients who exhibit bilateral amblyopia that is no longer responsive to conventional treatment.Entities:
Keywords: amblyopia; dichoptic training; orthoptic therapy; perceptual learning; vision therapy
Year: 2022 PMID: 35204925 PMCID: PMC8870234 DOI: 10.3390/children9020205
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Demographic data of case and control group.
| Study ( | Control ( | ||
|---|---|---|---|
| Age | 7.60 (0.74) | 7.63 (0.72) | 0.924 |
| Sex | 0.108 | ||
| Male | 6 (40.0%) | 11 (68.8%) | |
| Female | 9 (60.0%) | 5 (31.3%) | |
| History of patching | 0.693 | ||
| 2 (13.3%) | 3 (18.8%) | ||
| Anisometropia or Isometropia | 1.000 | ||
| A | 4 (26.7%) | 5 (31.3%) | |
| I | 11 (73.3%) | 11 (68.8%) | |
| Refractive error | |||
| 0 D to +1.00 D | 0 (0%) | 3 (18.8%) | |
| +1.00 D to <+2.00 D | 0 (0%) | 1 (6.2%) | |
| +2.00 D to <+3.00 D | 0 (0%) | 1 (6.2%) | |
| +3.00 D to <+4.00 D | 0 (0%) | 1 (6.2%) | |
| +4.00 D to <+5.00 D | 0 (0%) | 0 (0%) | |
| ≥+5.00 D | 1 (6.7%) | 2 (12.5%) | |
| −1.00 D to 0 D | 1 (6.7%) | 1 (6.2%) | |
| −2.00 D to <−1.00 D | 2 (13.3%) | 2 (12.5%) | |
| −3.00 D to <−2.00 D | 0 (0%) | 1 (6.2%) | |
| −4.00 D to <−3.00 D | 1 (6.7%) | 1 (6.2%) | |
| −5.00 D to <−4.00 D | 0 (0%) | 2 (12.5%) | |
| <−5.00 D | 10 (66.7%) | 1 (6.2%) | |
| Depth of Amblyopia | 0.3342 | ||
| severe (>0.7 logMAR) | 1 (6.7%) | 3 (18.7%) | |
| moderate (0.3 to 0.7 logMAR) | 8 (53.3%) | 10 (62.5%) | |
| mild (<0.3 logMAR) | 6 (40%) | 3 (18.7%) | |
| Mean follow up period (m) | 0.95 | ||
| 6.4 | 6.32 |
Values are presented as n (%) or mean (SD).; p value for chi square test or two independent t test.
Figure 1(a) Mean improvement in BCVA for the control and treatment groups (logMAR) (Mean ± Standard error) (b) The total change in BCVA for each patient (logMAR).
Difference between follow-up and baseline among 2 groups.
| Variables | Δ0−1 | Δ0−2 | Δ0−3 | Δ0−4 | Δ0-E | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | T |
| C | T |
| C | T |
| C | T |
| C | T |
| |
| Number | 24 | 30 | 16 | 12 | 8 | 8 | 8 | 4 | 32 | 30 | |||||
| logMAR | 0.00 (0.00, 0.08) | 0.20 (0.20, 0.33) | <0.001 * | 0.00 (0.00, 0.10) | 0.20 (0.20, 0.30) | <0.001 * | 0.00 (0.00, 0.10) | 0.35 (0.20, 0.58) | 0.001 * | 0.00 (−0.08, 0.00) | 0.45 (0.33, 0.58) | <0.001 * | 0.00 (0.00, 0.10) | 0.30 (0.20, 0.40) | <0.001 * |
C: Control group; T: Treatment group; Data presented as median (Q1, Q3). p value for Mann-Whitney U test. Δ0-1: Difference between 3rd month and baseline; Δ0-2: Difference between 6th month and baseline; Δ0-3: Difference between 9th month and baseline; Δ0-4: Difference between 12th month and baseline; Δ0-E: Difference between endpoint and baseline; *: p value less than 0.05.
Difference between follow-up and baseline.
| Baseline | 3rd m |
| Baseline | 6th m |
| Baseline | 9th m |
| Baseline | 12th m |
| Baseline | Endpoint |
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | 0.50 (0.33, 1.00) | 0.40 (0.33, 1.00) | 0.299 | 0.40 (0.30, 0.93) | 0.50 (0.20, 1.00) | 0.777 | 0.70 (0.30, 1.00) | 0.60 (0.20, 1.00) | 0.102 | 0.85 (0.40, 1.00) | 1.00 (0.28, 1.00) | 0.593 | 0.50 (0.33, 0.70) | 0.40 (0.30, 1.00) | 0.613 |
| Case | 0.30 (0.20, 0.40) | 0.00 (0.00, 0.20) | <0.001 * | 0.30 (0.20, 0.40) | 0.00 (0.00, 0.18) | 0.002 * | 0.45 (0.23, 0.65) | 0.05 (0.00, 0.10) | 0.011 * | 0.45 (0.33, 0.65) | 0.00 (0.00, 0.08) | 0.068 | 0.30 (0.20, 0.40) | 0.00 (0.00, 0.00) | <0.001 * |
Data presented as median (Q1, Q3). p value for Wilcoxon signed rank test. * Represent p value less than 0.05.
Figure 2The individual improvement in stereoacuity after vision therapy.